Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers

We began analyzing https://link.springer.com/chapter/10.1007/978-3-7643-8117-2_1, but it redirected us to https://link.springer.com/chapter/10.1007/978-3-7643-8117-2_1. The analysis below is for the second page.

Title[redir]:
Mother Nature’s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery | SpringerLink
Description:
This chapter is designed to demonstrate that compounds derived from nature are still in the forefront of drug discovery in diseases such as microbial and parasitic infections, carcinomas of many types and control of cholesterol/lipids in man. In each disease area we...

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, cas, pubmed, agents, chem, natural, drug, drugs, products, cancer, activity, chemother, synthesis, antimicrob, anticancer, newman, opin, antibiot, structure, clin, discovery, antibiotic, curr, med, nat, chapter, antibiotics, compounds, rev, vitro, cragg, lett, antitumor, clinical, boca, raton, isolation, eds, treatment, investig, action, inhibitors, cell, oncol, research, nature, prod, dgi, kingston,

Topics {✒️}

de-acetylglucosaminyl-deoxy teicoplanin active d-α-aminoadipic acid palladium-catalyzed bis-allylation lipase-catalyzed regioselective esterification cyclin-dependent kinase pathways anti-mrsa beta-lactams albumin-bound particle form weekly single-agent patupilone 6-o-substituted ketolides active month download article/chapter inhibit hmg-coa reductase n-phosphono type prodrug small-cell lung cancer 11-o-bridged bicyclic ketolides de la iglesia-vicente anti-mrsa cephalosporin t-91825 highly glycopeptide-resistant enterococci potential cholesterol-lowering agents penicillin-nonsusceptible streptococcus pneumoniae amrubicin induces apoptosis world scientific publishing privacy choices/manage cookies strong cell growth silva elipe mv device instant download streptococcus pneumoniae susceptible escherichia coli ribosome van goethem id acute myeloid leukemia van den bosch de souza nj b-lactam antibiotics biologically active substances endothelial cell transport transformed cell differentiation lilly research laboratories biologically active compounds ochoa-bayona jl microtubule stabilizing agents microtubule-stabilizing agents peptide bond formation chong kun dang developmental therapeutics program macrolide antibiotic studies disseminated infection caused endophyte fungal isolates combretastatin a-4 prodrugs de wilt jh albumin-bound paclitaxel mitochondrial membrane potential

Questions {❓}

  • Nilius AM, Ma Z (2002) Ketolides: The future of the macrolides?
  • Vagelos RP (1991) Are prescription drug prices too high?
  • Von Nussbaum F, Brands M, Hinzen B, Weigand S, Habich D (2006) Antibacterial natural products in medicinal chemistry —exodus or revival?

Schema {🗺️}

ScholarlyArticle:
      headline:Mother Nature’s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery
      pageEnd:44
      pageStart:1
      image:https://media.springernature.com/w153/springer-static/cover/book/978-3-7643-8117-2.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Natural Compounds as Drugs Volume I
         isbn:
            978-3-7643-8117-2
            978-3-7643-8098-4
         type:Book
      publisher:
         name:Birkhäuser Basel
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mark S. Butler
            affiliation:
                  name:MerLion Pharmaceuticals
                  address:
                     name:MerLion Pharmaceuticals, Singapore
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Newman
            affiliation:
                  name:Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick
                  address:
                     name:Fairview Center Suite 206, Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick, Frederick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Antimicrob Agent, Methicillin Resistant Staphylococcus Aureus, Gemtuzumab Ozogamicin, Expert Opin Investig Drug, Curr Opin Investig Drug
      description:This chapter is designed to demonstrate that compounds derived from nature are still in the forefront of drug discovery in diseases such as microbial and parasitic infections, carcinomas of many types and control of cholesterol/lipids in man. In each disease area we have provided short discussions of past, present and future agents, in general only considering compounds currently in clinical Phase II or later, that were/are derived from nature’s chemical skeletons. Finishing with a discussion of the current and evolving role(s) of microbes (bacteria and fungi) in the production of old and new agents ostensibly produced by higher organisms.
      datePublished:2008
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Natural Compounds as Drugs Volume I
      isbn:
         978-3-7643-8117-2
         978-3-7643-8098-4
Organization:
      name:Birkhäuser Basel
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:MerLion Pharmaceuticals
      address:
         name:MerLion Pharmaceuticals, Singapore
         type:PostalAddress
      name:Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick
      address:
         name:Fairview Center Suite 206, Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick, Frederick, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mark S. Butler
      affiliation:
            name:MerLion Pharmaceuticals
            address:
               name:MerLion Pharmaceuticals, Singapore
               type:PostalAddress
            type:Organization
      name:David J. Newman
      affiliation:
            name:Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick
            address:
               name:Fairview Center Suite 206, Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick, Frederick, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:MerLion Pharmaceuticals, Singapore
      name:Fairview Center Suite 206, Natural Products Branch, Developmental Therapeutics Program, NCI-Frederick, Frederick, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(589)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com
5.45s.